Clinical Trial Update: Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria [Phase 2, Phase 3]

View source ↗

Summary

A long-term safety and tolerability study of MY008211A tablets in paroxysmal nocturnal hemoglobinuria is enrolling in Phase 2 and Phase 3. The sponsor is Wuhan …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• MY008211A

Snippet

Sponsor: Wuhan Createrna Science and Technology Co., Ltd | Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2, Phase 3 | Status: RECRUITING